MiniMed Group, Inc. Common Stock
Get $10 bonus on your first $100 deposit for MMED
Get $10 bonus on your first $100 deposit for MMED
MiniMed Group, Inc. Common Stock (MMED) Stock Competitors & Peer Comparison
See (MMED) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Care Facilities Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| MMED | $15.21 | +5.70% | 4.3B | -16.18 | -$0.94 | N/A |
| HCA | $498.66 | +0.25% | 111.5B | 17.59 | $28.34 | +0.59% |
| THC | $196.60 | +1.87% | 17.3B | 12.69 | $15.50 | N/A |
| FMS | $23.21 | -2.15% | 13.4B | 11.80 | $1.97 | +3.38% |
| SOLV | $69.02 | +2.39% | 12B | 7.77 | $8.88 | N/A |
| UHS | $181.95 | -0.68% | 11.6B | 7.88 | $23.10 | +0.44% |
| ENSG | $198.45 | -0.92% | 11.5B | 34.04 | $5.83 | +0.13% |
| EHC | $106.70 | -0.80% | 10.7B | 19.23 | $5.55 | +0.69% |
| DVA | $149.45 | -1.39% | 10B | 15.72 | $9.51 | N/A |
| OSH | $39.00 | +0.08% | 9.5B | -17.65 | -$2.21 | N/A |
Stock Comparison
MMED vs HCA Comparison April 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.3B. In comparison, HCA has a market cap of 111.5B. Regarding current trading prices, MMED is priced at $15.21, while HCA trades at $498.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -16.18, whereas HCA's P/E ratio is 17.59. In terms of profitability, MMED's ROE is -0.07%, compared to HCA's ROE of -1.41%. Regarding short-term risk, MMED is more volatile compared to HCA. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check HCA's competition here
MMED vs THC Comparison April 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.3B. In comparison, THC has a market cap of 17.3B. Regarding current trading prices, MMED is priced at $15.21, while THC trades at $196.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -16.18, whereas THC's P/E ratio is 12.69. In terms of profitability, MMED's ROE is -0.07%, compared to THC's ROE of +0.35%. Regarding short-term risk, MMED is more volatile compared to THC. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check THC's competition here
MMED vs FMS Comparison April 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.3B. In comparison, FMS has a market cap of 13.4B. Regarding current trading prices, MMED is priced at $15.21, while FMS trades at $23.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -16.18, whereas FMS's P/E ratio is 11.80. In terms of profitability, MMED's ROE is -0.07%, compared to FMS's ROE of +0.07%. Regarding short-term risk, MMED is more volatile compared to FMS. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check FMS's competition here
MMED vs SOLV Comparison April 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.3B. In comparison, SOLV has a market cap of 12B. Regarding current trading prices, MMED is priced at $15.21, while SOLV trades at $69.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -16.18, whereas SOLV's P/E ratio is 7.77. In terms of profitability, MMED's ROE is -0.07%, compared to SOLV's ROE of +0.37%. Regarding short-term risk, MMED is more volatile compared to SOLV. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check SOLV's competition here
MMED vs UHS Comparison April 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.3B. In comparison, UHS has a market cap of 11.6B. Regarding current trading prices, MMED is priced at $15.21, while UHS trades at $181.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -16.18, whereas UHS's P/E ratio is 7.88. In terms of profitability, MMED's ROE is -0.07%, compared to UHS's ROE of +0.21%. Regarding short-term risk, MMED is more volatile compared to UHS. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check UHS's competition here
MMED vs ENSG Comparison April 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.3B. In comparison, ENSG has a market cap of 11.5B. Regarding current trading prices, MMED is priced at $15.21, while ENSG trades at $198.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -16.18, whereas ENSG's P/E ratio is 34.04. In terms of profitability, MMED's ROE is -0.07%, compared to ENSG's ROE of +0.17%. Regarding short-term risk, MMED is more volatile compared to ENSG. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check ENSG's competition here
MMED vs EHC Comparison April 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.3B. In comparison, EHC has a market cap of 10.7B. Regarding current trading prices, MMED is priced at $15.21, while EHC trades at $106.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -16.18, whereas EHC's P/E ratio is 19.23. In terms of profitability, MMED's ROE is -0.07%, compared to EHC's ROE of +0.24%. Regarding short-term risk, MMED is more volatile compared to EHC. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check EHC's competition here
MMED vs DVA Comparison April 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.3B. In comparison, DVA has a market cap of 10B. Regarding current trading prices, MMED is priced at $15.21, while DVA trades at $149.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -16.18, whereas DVA's P/E ratio is 15.72. In terms of profitability, MMED's ROE is -0.07%, compared to DVA's ROE of -1.61%. Regarding short-term risk, MMED is more volatile compared to DVA. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check DVA's competition here
MMED vs OSH Comparison April 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.3B. In comparison, OSH has a market cap of 9.5B. Regarding current trading prices, MMED is priced at $15.21, while OSH trades at $39.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -16.18, whereas OSH's P/E ratio is -17.65. In terms of profitability, MMED's ROE is -0.07%, compared to OSH's ROE of +4.64%. Regarding short-term risk, MMED is more volatile compared to OSH. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check OSH's competition here
MMED vs LHCG Comparison April 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.3B. In comparison, LHCG has a market cap of 5.3B. Regarding current trading prices, MMED is priced at $15.21, while LHCG trades at $169.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -16.18, whereas LHCG's P/E ratio is 82.83. In terms of profitability, MMED's ROE is -0.07%, compared to LHCG's ROE of +0.04%. Regarding short-term risk, MMED is more volatile compared to LHCG. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check LHCG's competition here
MMED vs CHE Comparison April 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.3B. In comparison, CHE has a market cap of 5.2B. Regarding current trading prices, MMED is priced at $15.21, while CHE trades at $376.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -16.18, whereas CHE's P/E ratio is 20.54. In terms of profitability, MMED's ROE is -0.07%, compared to CHE's ROE of +0.24%. Regarding short-term risk, MMED is more volatile compared to CHE. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check CHE's competition here
MMED vs OPCH Comparison April 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.3B. In comparison, OPCH has a market cap of 4.4B. Regarding current trading prices, MMED is priced at $15.21, while OPCH trades at $27.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -16.18, whereas OPCH's P/E ratio is 21.97. In terms of profitability, MMED's ROE is -0.07%, compared to OPCH's ROE of +0.15%. Regarding short-term risk, MMED is more volatile compared to OPCH. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check OPCH's competition here
MMED vs AMED Comparison April 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.3B. In comparison, AMED has a market cap of 3.3B. Regarding current trading prices, MMED is priced at $15.21, while AMED trades at $100.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -16.18, whereas AMED's P/E ratio is 39.30. In terms of profitability, MMED's ROE is -0.07%, compared to AMED's ROE of +0.09%. Regarding short-term risk, MMED is more volatile compared to AMED. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check AMED's competition here
MMED vs BKD Comparison April 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.3B. In comparison, BKD has a market cap of 3.3B. Regarding current trading prices, MMED is priced at $15.21, while BKD trades at $13.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -16.18, whereas BKD's P/E ratio is -12.44. In terms of profitability, MMED's ROE is -0.07%, compared to BKD's ROE of -5.24%. Regarding short-term risk, MMED is more volatile compared to BKD. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check BKD's competition here
MMED vs LFST Comparison April 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.3B. In comparison, LFST has a market cap of 2.5B. Regarding current trading prices, MMED is priced at $15.21, while LFST trades at $6.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -16.18, whereas LFST's P/E ratio is 325.50. In terms of profitability, MMED's ROE is -0.07%, compared to LFST's ROE of +0.01%. Regarding short-term risk, MMED is more volatile compared to LFST. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check LFST's competition here
MMED vs NHC Comparison April 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.3B. In comparison, NHC has a market cap of 2.5B. Regarding current trading prices, MMED is priced at $15.21, while NHC trades at $163.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -16.18, whereas NHC's P/E ratio is 21.28. In terms of profitability, MMED's ROE is -0.07%, compared to NHC's ROE of +0.12%. Regarding short-term risk, MMED is more volatile compared to NHC. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check NHC's competition here
MMED vs ACHC Comparison April 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.3B. In comparison, ACHC has a market cap of 2.4B. Regarding current trading prices, MMED is priced at $15.21, while ACHC trades at $26.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -16.18, whereas ACHC's P/E ratio is -2.18. In terms of profitability, MMED's ROE is -0.07%, compared to ACHC's ROE of -0.39%. Regarding short-term risk, MMED is more volatile compared to ACHC. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check ACHC's competition here
MMED vs SEM Comparison April 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.3B. In comparison, SEM has a market cap of 2B. Regarding current trading prices, MMED is priced at $15.21, while SEM trades at $16.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -16.18, whereas SEM's P/E ratio is 14.14. In terms of profitability, MMED's ROE is -0.07%, compared to SEM's ROE of +0.09%. Regarding short-term risk, MMED is more volatile compared to SEM. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check SEM's competition here
MMED vs MD Comparison April 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.3B. In comparison, MD has a market cap of 1.9B. Regarding current trading prices, MMED is priced at $15.21, while MD trades at $22.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -16.18, whereas MD's P/E ratio is 11.66. In terms of profitability, MMED's ROE is -0.07%, compared to MD's ROE of +0.20%. Regarding short-term risk, MMED is more volatile compared to MD. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check MD's competition here
MMED vs AMEH Comparison April 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.3B. In comparison, AMEH has a market cap of 1.8B. Regarding current trading prices, MMED is priced at $15.21, while AMEH trades at $40.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -16.18, whereas AMEH's P/E ratio is 39.25. In terms of profitability, MMED's ROE is -0.07%, compared to AMEH's ROE of +0.04%. Regarding short-term risk, MMED is more volatile compared to AMEH. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check AMEH's competition here
MMED vs ADUS Comparison April 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.3B. In comparison, ADUS has a market cap of 1.7B. Regarding current trading prices, MMED is priced at $15.21, while ADUS trades at $93.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -16.18, whereas ADUS's P/E ratio is 17.86. In terms of profitability, MMED's ROE is -0.07%, compared to ADUS's ROE of +0.09%. Regarding short-term risk, MMED is more volatile compared to ADUS. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check ADUS's competition here
MMED vs SGRY Comparison April 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.3B. In comparison, SGRY has a market cap of 1.7B. Regarding current trading prices, MMED is priced at $15.21, while SGRY trades at $13.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -16.18, whereas SGRY's P/E ratio is -21.48. In terms of profitability, MMED's ROE is -0.07%, compared to SGRY's ROE of -0.04%. Regarding short-term risk, MMED is more volatile compared to SGRY. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check SGRY's competition here
MMED vs ASTH Comparison April 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.3B. In comparison, ASTH has a market cap of 1.5B. Regarding current trading prices, MMED is priced at $15.21, while ASTH trades at $29.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -16.18, whereas ASTH's P/E ratio is 63.20. In terms of profitability, MMED's ROE is -0.07%, compared to ASTH's ROE of +0.03%. Regarding short-term risk, MMED is more volatile compared to ASTH. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check ASTH's competition here
MMED vs AVAH Comparison April 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.3B. In comparison, AVAH has a market cap of 1.4B. Regarding current trading prices, MMED is priced at $15.21, while AVAH trades at $6.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -16.18, whereas AVAH's P/E ratio is 6.31. In terms of profitability, MMED's ROE is -0.07%, compared to AVAH's ROE of +9.53%. Regarding short-term risk, MMED is more volatile compared to AVAH. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check AVAH's competition here
MMED vs ARDT Comparison April 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.3B. In comparison, ARDT has a market cap of 1.3B. Regarding current trading prices, MMED is priced at $15.21, while ARDT trades at $9.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -16.18, whereas ARDT's P/E ratio is 9.81. In terms of profitability, MMED's ROE is -0.07%, compared to ARDT's ROE of +0.10%. Regarding short-term risk, MMED is more volatile compared to ARDT. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check ARDT's competition here
MMED vs HCSG Comparison April 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.3B. In comparison, HCSG has a market cap of 1.3B. Regarding current trading prices, MMED is priced at $15.21, while HCSG trades at $19.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -16.18, whereas HCSG's P/E ratio is 23.49. In terms of profitability, MMED's ROE is -0.07%, compared to HCSG's ROE of +0.12%. Regarding short-term risk, MMED is more volatile compared to HCSG. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check HCSG's competition here
MMED vs BKDT Comparison April 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.3B. In comparison, BKDT has a market cap of 1.2B. Regarding current trading prices, MMED is priced at $15.21, while BKDT trades at $77.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -16.18, whereas BKDT's P/E ratio is N/A. In terms of profitability, MMED's ROE is -0.07%, compared to BKDT's ROE of -5.24%. Regarding short-term risk, MMED is more volatile compared to BKDT. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check BKDT's competition here
MMED vs USPH Comparison April 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.3B. In comparison, USPH has a market cap of 1.2B. Regarding current trading prices, MMED is priced at $15.21, while USPH trades at $77.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -16.18, whereas USPH's P/E ratio is 54.35. In terms of profitability, MMED's ROE is -0.07%, compared to USPH's ROE of +0.03%. Regarding short-term risk, MMED is more volatile compared to USPH. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check USPH's competition here
MMED vs INNV Comparison April 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.3B. In comparison, INNV has a market cap of 1.1B. Regarding current trading prices, MMED is priced at $15.21, while INNV trades at $8.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -16.18, whereas INNV's P/E ratio is 163.40. In terms of profitability, MMED's ROE is -0.07%, compared to INNV's ROE of -0.02%. Regarding short-term risk, MMED is more volatile compared to INNV. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check INNV's competition here
MMED vs PNTG Comparison April 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.3B. In comparison, PNTG has a market cap of 1.1B. Regarding current trading prices, MMED is priced at $15.21, while PNTG trades at $30.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -16.18, whereas PNTG's P/E ratio is 36.49. In terms of profitability, MMED's ROE is -0.07%, compared to PNTG's ROE of +0.09%. Regarding short-term risk, MMED is more volatile compared to PNTG. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check PNTG's competition here
MMED vs TALK Comparison April 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.3B. In comparison, TALK has a market cap of 863.8M. Regarding current trading prices, MMED is priced at $15.21, while TALK trades at $5.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -16.18, whereas TALK's P/E ratio is 129.25. In terms of profitability, MMED's ROE is -0.07%, compared to TALK's ROE of +0.07%. Regarding short-term risk, MMED is more volatile compared to TALK. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check TALK's competition here
MMED vs FSHCX Comparison April 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.3B. In comparison, FSHCX has a market cap of 863.1M. Regarding current trading prices, MMED is priced at $15.21, while FSHCX trades at $99.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -16.18, whereas FSHCX's P/E ratio is N/A. In terms of profitability, MMED's ROE is -0.07%, compared to FSHCX's ROE of N/A. Regarding short-term risk, MMED is more volatile compared to FSHCX. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check FSHCX's competition here
MMED vs AMN Comparison April 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.3B. In comparison, AMN has a market cap of 724.7M. Regarding current trading prices, MMED is priced at $15.21, while AMN trades at $18.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -16.18, whereas AMN's P/E ratio is -7.56. In terms of profitability, MMED's ROE is -0.07%, compared to AMN's ROE of -0.15%. Regarding short-term risk, MMED is more volatile compared to AMN. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check AMN's competition here
MMED vs EHAB Comparison April 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.3B. In comparison, EHAB has a market cap of 705.6M. Regarding current trading prices, MMED is priced at $15.21, while EHAB trades at $13.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -16.18, whereas EHAB's P/E ratio is -154.56. In terms of profitability, MMED's ROE is -0.07%, compared to EHAB's ROE of -0.01%. Regarding short-term risk, MMED is more volatile compared to EHAB. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check EHAB's competition here
MMED vs SNDA Comparison April 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.3B. In comparison, SNDA has a market cap of 621.8M. Regarding current trading prices, MMED is priced at $15.21, while SNDA trades at $34.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -16.18, whereas SNDA's P/E ratio is -8.15. In terms of profitability, MMED's ROE is -0.07%, compared to SNDA's ROE of -0.81%. Regarding short-term risk, MMED is more volatile compared to SNDA. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check SNDA's competition here
MMED vs CMPS Comparison April 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.3B. In comparison, CMPS has a market cap of 552.5M. Regarding current trading prices, MMED is priced at $15.21, while CMPS trades at $5.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -16.18, whereas CMPS's P/E ratio is -1.87. In terms of profitability, MMED's ROE is -0.07%, compared to CMPS's ROE of -3.36%. Regarding short-term risk, MMED is more volatile compared to CMPS. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check CMPS's competition here
MMED vs MCTA Comparison April 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.3B. In comparison, MCTA has a market cap of 445.6M. Regarding current trading prices, MMED is priced at $15.21, while MCTA trades at $29.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -16.18, whereas MCTA's P/E ratio is 419.36. In terms of profitability, MMED's ROE is -0.07%, compared to MCTA's ROE of -2.33%. Regarding short-term risk, MMED is more volatile compared to MCTA. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check MCTA's competition here
MMED vs CYH Comparison April 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.3B. In comparison, CYH has a market cap of 427M. Regarding current trading prices, MMED is priced at $15.21, while CYH trades at $3.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -16.18, whereas CYH's P/E ratio is 0.82. In terms of profitability, MMED's ROE is -0.07%, compared to CYH's ROE of -0.32%. Regarding short-term risk, MMED is more volatile compared to CYH. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check CYH's competition here
MMED vs AUNA Comparison April 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.3B. In comparison, AUNA has a market cap of 409.3M. Regarding current trading prices, MMED is priced at $15.21, while AUNA trades at $5.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -16.18, whereas AUNA's P/E ratio is 14.55. In terms of profitability, MMED's ROE is -0.07%, compared to AUNA's ROE of +0.06%. Regarding short-term risk, MMED is more volatile compared to AUNA. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check AUNA's competition here
MMED vs AGL Comparison April 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.3B. In comparison, AGL has a market cap of 375.5M. Regarding current trading prices, MMED is priced at $15.21, while AGL trades at $22.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -16.18, whereas AGL's P/E ratio is -0.92. In terms of profitability, MMED's ROE is -0.07%, compared to AGL's ROE of -1.17%. Regarding short-term risk, MMED is less volatile compared to AGL. This indicates potentially lower risk in terms of short-term price fluctuations for MMED.Check AGL's competition here
MMED vs TOI Comparison April 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.3B. In comparison, TOI has a market cap of 334.1M. Regarding current trading prices, MMED is priced at $15.21, while TOI trades at $3.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -16.18, whereas TOI's P/E ratio is -6.26. In terms of profitability, MMED's ROE is -0.07%, compared to TOI's ROE of +7.60%. Regarding short-term risk, MMED is more volatile compared to TOI. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check TOI's competition here
MMED vs CCRN Comparison April 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.3B. In comparison, CCRN has a market cap of 315.8M. Regarding current trading prices, MMED is priced at $15.21, while CCRN trades at $9.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -16.18, whereas CCRN's P/E ratio is -3.33. In terms of profitability, MMED's ROE is -0.07%, compared to CCRN's ROE of -0.24%. Regarding short-term risk, MMED is more volatile compared to CCRN. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check CCRN's competition here
MMED vs CSU Comparison April 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.3B. In comparison, CSU has a market cap of 223.7M. Regarding current trading prices, MMED is priced at $15.21, while CSU trades at $33.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -16.18, whereas CSU's P/E ratio is 0.67. In terms of profitability, MMED's ROE is -0.07%, compared to CSU's ROE of -2.10%. Regarding short-term risk, MMED is more volatile compared to CSU. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check CSU's competition here
MMED vs AONC Comparison April 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.3B. In comparison, AONC has a market cap of 216.4M. Regarding current trading prices, MMED is priced at $15.21, while AONC trades at $7.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -16.18, whereas AONC's P/E ratio is -8.31. In terms of profitability, MMED's ROE is -0.07%, compared to AONC's ROE of +0.06%. Regarding short-term risk, MMED is more volatile compared to AONC. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check AONC's competition here
MMED vs AIRS Comparison April 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.3B. In comparison, AIRS has a market cap of 184.8M. Regarding current trading prices, MMED is priced at $15.21, while AIRS trades at $2.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -16.18, whereas AIRS's P/E ratio is -13.79. In terms of profitability, MMED's ROE is -0.07%, compared to AIRS's ROE of -0.14%. Regarding short-term risk, MMED is less volatile compared to AIRS. This indicates potentially lower risk in terms of short-term price fluctuations for MMED.Check AIRS's competition here
MMED vs JYNT Comparison April 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.3B. In comparison, JYNT has a market cap of 128.6M. Regarding current trading prices, MMED is priced at $15.21, while JYNT trades at $8.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -16.18, whereas JYNT's P/E ratio is -449.00. In terms of profitability, MMED's ROE is -0.07%, compared to JYNT's ROE of +0.14%. Regarding short-term risk, MMED is more volatile compared to JYNT. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check JYNT's competition here
MMED vs NAKAW Comparison April 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.3B. In comparison, NAKAW has a market cap of 116.4M. Regarding current trading prices, MMED is priced at $15.21, while NAKAW trades at $15.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -16.18, whereas NAKAW's P/E ratio is N/A. In terms of profitability, MMED's ROE is -0.07%, compared to NAKAW's ROE of -0.21%. Regarding short-term risk, MMED is less volatile compared to NAKAW. This indicates potentially lower risk in terms of short-term price fluctuations for MMED.Check NAKAW's competition here
MMED vs FVE Comparison April 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.3B. In comparison, FVE has a market cap of 98.4M. Regarding current trading prices, MMED is priced at $15.21, while FVE trades at $2.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -16.18, whereas FVE's P/E ratio is -5.64. In terms of profitability, MMED's ROE is -0.07%, compared to FVE's ROE of -0.15%. Regarding short-term risk, MMED is more volatile compared to FVE. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check FVE's competition here
MMED vs KDLYW Comparison April 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.3B. In comparison, KDLYW has a market cap of 96.5M. Regarding current trading prices, MMED is priced at $15.21, while KDLYW trades at $18.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -16.18, whereas KDLYW's P/E ratio is N/A. In terms of profitability, MMED's ROE is -0.07%, compared to KDLYW's ROE of -0.21%. Regarding short-term risk, MMED is less volatile compared to KDLYW. This indicates potentially lower risk in terms of short-term price fluctuations for MMED.Check KDLYW's competition here
MMED vs BTMD Comparison April 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.3B. In comparison, BTMD has a market cap of 82M. Regarding current trading prices, MMED is priced at $15.21, while BTMD trades at $1.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -16.18, whereas BTMD's P/E ratio is 2.51. In terms of profitability, MMED's ROE is -0.07%, compared to BTMD's ROE of -0.35%. Regarding short-term risk, MMED is less volatile compared to BTMD. This indicates potentially lower risk in terms of short-term price fluctuations for MMED.Check BTMD's competition here
MMED vs DCGO Comparison April 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.3B. In comparison, DCGO has a market cap of 53.2M. Regarding current trading prices, MMED is priced at $15.21, while DCGO trades at $0.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -16.18, whereas DCGO's P/E ratio is -0.28. In terms of profitability, MMED's ROE is -0.07%, compared to DCGO's ROE of -0.71%. Regarding short-term risk, MMED is less volatile compared to DCGO. This indicates potentially lower risk in terms of short-term price fluctuations for MMED.Check DCGO's competition here
MMED vs ALR Comparison April 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.3B. In comparison, ALR has a market cap of 44.2M. Regarding current trading prices, MMED is priced at $15.21, while ALR trades at $1.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -16.18, whereas ALR's P/E ratio is -1.11. In terms of profitability, MMED's ROE is -0.07%, compared to ALR's ROE of -0.15%. Regarding short-term risk, MMED is more volatile compared to ALR. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check ALR's competition here
MMED vs IMAC Comparison April 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.3B. In comparison, IMAC has a market cap of 33.1M. Regarding current trading prices, MMED is priced at $15.21, while IMAC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -16.18, whereas IMAC's P/E ratio is -2.27. In terms of profitability, MMED's ROE is -0.07%, compared to IMAC's ROE of +1183.61%. Regarding short-term risk, MMED is more volatile compared to IMAC. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check IMAC's competition here
MMED vs CCEL Comparison April 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.3B. In comparison, CCEL has a market cap of 29.6M. Regarding current trading prices, MMED is priced at $15.21, while CCEL trades at $3.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -16.18, whereas CCEL's P/E ratio is -12.23. In terms of profitability, MMED's ROE is -0.07%, compared to CCEL's ROE of +0.15%. Regarding short-term risk, MMED is less volatile compared to CCEL. This indicates potentially lower risk in terms of short-term price fluctuations for MMED.Check CCEL's competition here
MMED vs CANO-WT Comparison April 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.3B. In comparison, CANO-WT has a market cap of 19.3M. Regarding current trading prices, MMED is priced at $15.21, while CANO-WT trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -16.18, whereas CANO-WT's P/E ratio is N/A. In terms of profitability, MMED's ROE is -0.07%, compared to CANO-WT's ROE of -1.49%. Regarding short-term risk, MMED is less volatile compared to CANO-WT. This indicates potentially lower risk in terms of short-term price fluctuations for MMED.Check CANO-WT's competition here
MMED vs AIH Comparison April 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.3B. In comparison, AIH has a market cap of 15.9M. Regarding current trading prices, MMED is priced at $15.21, while AIH trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -16.18, whereas AIH's P/E ratio is -2.78. In terms of profitability, MMED's ROE is -0.07%, compared to AIH's ROE of +1.16%. Regarding short-term risk, MMED is less volatile compared to AIH. This indicates potentially lower risk in terms of short-term price fluctuations for MMED.Check AIH's competition here
MMED vs CANO Comparison April 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.3B. In comparison, CANO has a market cap of 12.4M. Regarding current trading prices, MMED is priced at $15.21, while CANO trades at $2.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -16.18, whereas CANO's P/E ratio is -0.01. In terms of profitability, MMED's ROE is -0.07%, compared to CANO's ROE of -1.49%. Regarding short-term risk, MMED is less volatile compared to CANO. This indicates potentially lower risk in terms of short-term price fluctuations for MMED.Check CANO's competition here
MMED vs FTRP Comparison April 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.3B. In comparison, FTRP has a market cap of 9.8M. Regarding current trading prices, MMED is priced at $15.21, while FTRP trades at $0.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -16.18, whereas FTRP's P/E ratio is -1.22. In terms of profitability, MMED's ROE is -0.07%, compared to FTRP's ROE of -0.62%. Regarding short-term risk, MMED is more volatile compared to FTRP. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check FTRP's competition here
MMED vs AMS Comparison April 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.3B. In comparison, AMS has a market cap of 8.6M. Regarding current trading prices, MMED is priced at $15.21, while AMS trades at $1.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -16.18, whereas AMS's P/E ratio is -5.65. In terms of profitability, MMED's ROE is -0.07%, compared to AMS's ROE of -0.06%. Regarding short-term risk, MMED is less volatile compared to AMS. This indicates potentially lower risk in terms of short-term price fluctuations for MMED.Check AMS's competition here
MMED vs PIII Comparison April 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.3B. In comparison, PIII has a market cap of 8.1M. Regarding current trading prices, MMED is priced at $15.21, while PIII trades at $2.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -16.18, whereas PIII's P/E ratio is -0.05. In terms of profitability, MMED's ROE is -0.07%, compared to PIII's ROE of +8.94%. Regarding short-term risk, MMED is less volatile compared to PIII. This indicates potentially lower risk in terms of short-term price fluctuations for MMED.Check PIII's competition here
MMED vs MODV Comparison April 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.3B. In comparison, MODV has a market cap of 6.2M. Regarding current trading prices, MMED is priced at $15.21, while MODV trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -16.18, whereas MODV's P/E ratio is -0.03. In terms of profitability, MMED's ROE is -0.07%, compared to MODV's ROE of +1.84%. Regarding short-term risk, MMED is more volatile compared to MODV. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check MODV's competition here
MMED vs SYRA Comparison April 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.3B. In comparison, SYRA has a market cap of 5.8M. Regarding current trading prices, MMED is priced at $15.21, while SYRA trades at $0.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -16.18, whereas SYRA's P/E ratio is -3.68. In terms of profitability, MMED's ROE is -0.07%, compared to SYRA's ROE of -0.39%. Regarding short-term risk, MMED is less volatile compared to SYRA. This indicates potentially lower risk in terms of short-term price fluctuations for MMED.Check SYRA's competition here
MMED vs GBNH Comparison April 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.3B. In comparison, GBNH has a market cap of 5.5M. Regarding current trading prices, MMED is priced at $15.21, while GBNH trades at $0.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -16.18, whereas GBNH's P/E ratio is -0.06. In terms of profitability, MMED's ROE is -0.07%, compared to GBNH's ROE of +15.74%. Regarding short-term risk, MMED is less volatile compared to GBNH. This indicates potentially lower risk in terms of short-term price fluctuations for MMED.Check GBNH's competition here
MMED vs RHE-PA Comparison April 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.3B. In comparison, RHE-PA has a market cap of 5.2M. Regarding current trading prices, MMED is priced at $15.21, while RHE-PA trades at $0.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -16.18, whereas RHE-PA's P/E ratio is -0.09. In terms of profitability, MMED's ROE is -0.07%, compared to RHE-PA's ROE of -9.49%. Regarding short-term risk, MMED is less volatile compared to RHE-PA. This indicates potentially lower risk in terms of short-term price fluctuations for MMED.Check RHE-PA's competition here
MMED vs RHE Comparison April 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.3B. In comparison, RHE has a market cap of 5.2M. Regarding current trading prices, MMED is priced at $15.21, while RHE trades at $2.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -16.18, whereas RHE's P/E ratio is -1.79. In terms of profitability, MMED's ROE is -0.07%, compared to RHE's ROE of -0.00%. Regarding short-term risk, MMED is less volatile compared to RHE. This indicates potentially lower risk in terms of short-term price fluctuations for MMED.Check RHE's competition here
MMED vs TOIIW Comparison April 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.3B. In comparison, TOIIW has a market cap of 4.8M. Regarding current trading prices, MMED is priced at $15.21, while TOIIW trades at $0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -16.18, whereas TOIIW's P/E ratio is N/A. In terms of profitability, MMED's ROE is -0.07%, compared to TOIIW's ROE of +7.60%. Regarding short-term risk, MMED is more volatile compared to TOIIW. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check TOIIW's competition here
MMED vs ATIP Comparison April 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.3B. In comparison, ATIP has a market cap of 3M. Regarding current trading prices, MMED is priced at $15.21, while ATIP trades at $0.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -16.18, whereas ATIP's P/E ratio is -0.03. In terms of profitability, MMED's ROE is -0.07%, compared to ATIP's ROE of +2.05%. Regarding short-term risk, MMED is less volatile compared to ATIP. This indicates potentially lower risk in terms of short-term price fluctuations for MMED.Check ATIP's competition here
MMED vs IMACW Comparison April 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.3B. In comparison, IMACW has a market cap of 1.7M. Regarding current trading prices, MMED is priced at $15.21, while IMACW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -16.18, whereas IMACW's P/E ratio is N/A. In terms of profitability, MMED's ROE is -0.07%, compared to IMACW's ROE of +1.05%. Regarding short-term risk, MMED is less volatile compared to IMACW. This indicates potentially lower risk in terms of short-term price fluctuations for MMED.Check IMACW's competition here
MMED vs MNDR Comparison April 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.3B. In comparison, MNDR has a market cap of 740K. Regarding current trading prices, MMED is priced at $15.21, while MNDR trades at $0.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -16.18, whereas MNDR's P/E ratio is -0.35. In terms of profitability, MMED's ROE is -0.07%, compared to MNDR's ROE of -0.46%. Regarding short-term risk, MMED is more volatile compared to MNDR. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check MNDR's competition here
MMED vs CCM Comparison April 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.3B. In comparison, CCM has a market cap of 583.9K. Regarding current trading prices, MMED is priced at $15.21, while CCM trades at $4.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -16.18, whereas CCM's P/E ratio is -0.73. In terms of profitability, MMED's ROE is -0.07%, compared to CCM's ROE of +0.04%. Regarding short-term risk, MMED is more volatile compared to CCM. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check CCM's competition here
MMED vs TALKW Comparison April 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.3B. In comparison, TALKW has a market cap of 359K. Regarding current trading prices, MMED is priced at $15.21, while TALKW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -16.18, whereas TALKW's P/E ratio is N/A. In terms of profitability, MMED's ROE is -0.07%, compared to TALKW's ROE of +0.07%. Regarding short-term risk, MMED is less volatile compared to TALKW. This indicates potentially lower risk in terms of short-term price fluctuations for MMED.Check TALKW's competition here
MMED vs BACK Comparison April 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.3B. In comparison, BACK has a market cap of 208.2K. Regarding current trading prices, MMED is priced at $15.21, while BACK trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -16.18, whereas BACK's P/E ratio is -0.02. In terms of profitability, MMED's ROE is -0.07%, compared to BACK's ROE of +1.05%. Regarding short-term risk, MMED is less volatile compared to BACK. This indicates potentially lower risk in terms of short-term price fluctuations for MMED.Check BACK's competition here
MMED vs NVOS Comparison April 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.3B. In comparison, NVOS has a market cap of 69.1K. Regarding current trading prices, MMED is priced at $15.21, while NVOS trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -16.18, whereas NVOS's P/E ratio is N/A. In terms of profitability, MMED's ROE is -0.07%, compared to NVOS's ROE of -0.81%. Regarding short-term risk, MMED is more volatile compared to NVOS. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check NVOS's competition here
MMED vs NIVFW Comparison April 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.3B. In comparison, NIVFW has a market cap of 30.2K. Regarding current trading prices, MMED is priced at $15.21, while NIVFW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -16.18, whereas NIVFW's P/E ratio is N/A. In terms of profitability, MMED's ROE is -0.07%, compared to NIVFW's ROE of +0.33%. Regarding short-term risk, MMED is less volatile compared to NIVFW. This indicates potentially lower risk in terms of short-term price fluctuations for MMED.Check NIVFW's competition here
MMED vs PIIIW Comparison April 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.3B. In comparison, PIIIW has a market cap of 17.7K. Regarding current trading prices, MMED is priced at $15.21, while PIIIW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -16.18, whereas PIIIW's P/E ratio is N/A. In terms of profitability, MMED's ROE is -0.07%, compared to PIIIW's ROE of +8.94%. Regarding short-term risk, MMED is less volatile compared to PIIIW. This indicates potentially lower risk in terms of short-term price fluctuations for MMED.Check PIIIW's competition here
MMED vs IONM Comparison April 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.3B. In comparison, IONM has a market cap of 1.6K. Regarding current trading prices, MMED is priced at $15.21, while IONM trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -16.18, whereas IONM's P/E ratio is N/A. In terms of profitability, MMED's ROE is -0.07%, compared to IONM's ROE of +5.28%. Regarding short-term risk, MMED is less volatile compared to IONM. This indicates potentially lower risk in terms of short-term price fluctuations for MMED.Check IONM's competition here
MMED vs ATIP-WT Comparison April 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.3B. In comparison, ATIP-WT has a market cap of 0. Regarding current trading prices, MMED is priced at $15.21, while ATIP-WT trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -16.18, whereas ATIP-WT's P/E ratio is N/A. In terms of profitability, MMED's ROE is -0.07%, compared to ATIP-WT's ROE of +2.05%. Regarding short-term risk, MMED is less volatile compared to ATIP-WT. This indicates potentially lower risk in terms of short-term price fluctuations for MMED.Check ATIP-WT's competition here
MMED vs NFH Comparison April 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.3B. In comparison, NFH has a market cap of 0. Regarding current trading prices, MMED is priced at $15.21, while NFH trades at $11.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -16.18, whereas NFH's P/E ratio is -19.75. In terms of profitability, MMED's ROE is -0.07%, compared to NFH's ROE of -0.06%. Regarding short-term risk, MMED is more volatile compared to NFH. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check NFH's competition here
MMED vs TLMD Comparison April 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.3B. In comparison, TLMD has a market cap of 0. Regarding current trading prices, MMED is priced at $15.21, while TLMD trades at $3.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -16.18, whereas TLMD's P/E ratio is -1.60. In terms of profitability, MMED's ROE is -0.07%, compared to TLMD's ROE of -0.46%. Regarding short-term risk, MMED is more volatile compared to TLMD. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check TLMD's competition here
MMED vs SLHGP Comparison April 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.3B. In comparison, SLHGP has a market cap of 0. Regarding current trading prices, MMED is priced at $15.21, while SLHGP trades at $12.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -16.18, whereas SLHGP's P/E ratio is -30.38. In terms of profitability, MMED's ROE is -0.07%, compared to SLHGP's ROE of -0.71%. Regarding short-term risk, MMED is more volatile compared to SLHGP. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check SLHGP's competition here
MMED vs SLHG Comparison April 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.3B. In comparison, SLHG has a market cap of 0. Regarding current trading prices, MMED is priced at $15.21, while SLHG trades at $0.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -16.18, whereas SLHG's P/E ratio is -1.48. In terms of profitability, MMED's ROE is -0.07%, compared to SLHG's ROE of N/A. Regarding short-term risk, MMED is less volatile compared to SLHG. This indicates potentially lower risk in terms of short-term price fluctuations for MMED.Check SLHG's competition here
MMED vs AFAM Comparison April 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.3B. In comparison, AFAM has a market cap of 0. Regarding current trading prices, MMED is priced at $15.21, while AFAM trades at $56.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -16.18, whereas AFAM's P/E ratio is N/A. In terms of profitability, MMED's ROE is -0.07%, compared to AFAM's ROE of +0.06%. Regarding short-term risk, MMED is more volatile compared to AFAM. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check AFAM's competition here
MMED vs TVTY Comparison April 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.3B. In comparison, TVTY has a market cap of 0. Regarding current trading prices, MMED is priced at $15.21, while TVTY trades at $32.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -16.18, whereas TVTY's P/E ratio is 19.06. In terms of profitability, MMED's ROE is -0.07%, compared to TVTY's ROE of +1.75%. Regarding short-term risk, MMED is more volatile compared to TVTY. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check TVTY's competition here
MMED vs TLMDW Comparison April 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.3B. In comparison, TLMDW has a market cap of 0. Regarding current trading prices, MMED is priced at $15.21, while TLMDW trades at $0.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -16.18, whereas TLMDW's P/E ratio is N/A. In terms of profitability, MMED's ROE is -0.07%, compared to TLMDW's ROE of -0.46%. Regarding short-term risk, MMED is more volatile compared to TLMDW. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check TLMDW's competition here
MMED vs DCGOW Comparison April 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.3B. In comparison, DCGOW has a market cap of 0. Regarding current trading prices, MMED is priced at $15.21, while DCGOW trades at $1.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -16.18, whereas DCGOW's P/E ratio is N/A. In terms of profitability, MMED's ROE is -0.07%, compared to DCGOW's ROE of -0.71%. Regarding short-term risk, MMED is more volatile compared to DCGOW. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check DCGOW's competition here
MMED vs HNGR Comparison April 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.3B. In comparison, HNGR has a market cap of 0. Regarding current trading prices, MMED is priced at $15.21, while HNGR trades at $18.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -16.18, whereas HNGR's P/E ratio is 19.71. In terms of profitability, MMED's ROE is -0.07%, compared to HNGR's ROE of +0.52%. Regarding short-term risk, MMED is more volatile compared to HNGR. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check HNGR's competition here
MMED vs KND Comparison April 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.3B. In comparison, KND has a market cap of 0. Regarding current trading prices, MMED is priced at $15.21, while KND trades at $9.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -16.18, whereas KND's P/E ratio is N/A. In terms of profitability, MMED's ROE is -0.07%, compared to KND's ROE of -0.53%. Regarding short-term risk, MMED is more volatile compared to KND. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check KND's competition here
MMED vs DVCR Comparison April 2026
MMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MMED stands at 4.3B. In comparison, DVCR has a market cap of 0. Regarding current trading prices, MMED is priced at $15.21, while DVCR trades at $10.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MMED currently has a P/E ratio of -16.18, whereas DVCR's P/E ratio is 28.34. In terms of profitability, MMED's ROE is -0.07%, compared to DVCR's ROE of -0.15%. Regarding short-term risk, MMED is more volatile compared to DVCR. This indicates potentially higher risk in terms of short-term price fluctuations for MMED.Check DVCR's competition here